Allogeneic Adipose-Derived Mesenchymal Stem Cells (Horse Allo 20) for the Treatment of Osteoarthritis-Associated Lameness in Horses: Characterization,Safety,and Efficacy of Intra-Articular Treatment
Restricted accessResearch articleFirst published online September, 2018
Allogeneic Adipose-Derived Mesenchymal Stem Cells (Horse Allo 20) for the Treatment of Osteoarthritis-Associated Lameness in Horses: Characterization,Safety,and Efficacy of Intra-Articular Treatment
Osteoarthritis commonly causes lameness in the horse and has a great impact in performance animals. Due to the limitations of current medical therapies, allogenic mesenchymal stem cells (MSCs) may become an alternative method to control inflammation, reduce tissue damage and pain, and therefore improve lameness. We present the results of a regulatory clinical trial testing adipose-derived MSCs (Horse Allo 20) in veterinary (Agencia Española del Medicamento y Productos Sanitarios, Spanish Medicines Agency, Reference number 325/ECV) involving a total number of 80 participants and with 90 days of follow-up period. The manufacturing process of Horse Allo 20 was robust with no influence of the adipose tissue donor (gender, age, or breed), sample origin (intraperitoneal or subcutaneous), or storage conditions (fresh vs. frozen product presentations) on the quality, safety, and efficacy of the drug product. An in vivo safety study showed that local and systemic tolerance was safe even after repeated intra-articular administration (three injections). An in vivo efficacy study demonstrated the efficacy of the treatment after one or two injections by a reduction in lameness (P < 0.05) for an extended period of time (90 days), decreasing the need for prolonged local and/or systemic anti-inflammatory therapies and their well-known deleterious effects and toxicities.
Get full access to this article
View all access options for this article.
References
1.
WenC, LuWW and ChiuKY. (2014). Importance of subchondral bone in the pathogenesis and management of osteoarthritis from bench to bed. J Orthop Transl, 2:16–25.
2.
McIlwraithCW. (2010). The use of intra-articular corticosteroids in the horse: what is known on a scientific basis?. Equine Vet J, 42:563–571.
3.
GoodrichLR and NixonAJ. (2006). Medical treatment of osteoarthritis in the horse—a review. Vet J, 171:51–69.
4.
WehlingP, EvansC, WehlingJ and MaixnerW. (2017). Effectiveness of intra-articular therapies in osteoarthritis: a literature review. Ther Adv Musculoskelet Dis, 9:183–196.
5.
AnkrumJA, OngJF and KarpJM. (2014). Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol, 32:252–260.
6.
SchlueterAE and OrthMW. (2004). Equine osteoarthritis: a brief review of the disease and its causes. Equine Comp Exerc Physiol. 1:221–231.
7.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseDS, DeansRJ, KeatingA, ProckopDJ and HorwitzEM. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
8.
De SchauwerC, MeyerE, Van de WalleGR and Van SoomA. (2011). Markers of stemness in equine mesenchymal stem cells: a plea for uniformity. Theriogenology, 75:1431–1443.
9.
De SchauwerC, PiepersS, Van de WalleGR, DemeyereK, HoogewijsMK, GovaereJLJ, BraeckmansK, Van SoomA and MeyerE. (2012). In search for cross-reactivity to immunophenotype equine mesenchymal stromal cells by multicolor flow cytometry. Cytometry A, 81:312–323.
10.
PaebstF, PiehlerD, BrehmW, HellerS, SchroeckC, TárnokA and BurkJ. (2014). Comparative immunophenotyping of equine multipotent mesenchymal stromal cells: an approach toward a standardized definition. Cytometry A, 85:678–687.
11.
RozemullerH, PrinsH-J, NaaijkensB, StaalJ, BühringHJ and MartensAC. (2010). Prospective isolation of mesenchymal stem cells from multiple mammalian species using cross-reacting anti-human monoclonal antibodies. Stem Cells Dev, 19:1911–1921.
12.
CalloniR, ViegasGS, TürckP, BonattoD and Pegas HenriquesJA. (2014). Mesenchymal stromal cells from unconventional model organisms. Cytotherapy, 16:3–16.
13.
BurkJ, BadylakSF, KellyJ and BrehmW. (2013). Equine cellular therapy—from stall to bench to bedside?. Cytometry A, 83:103–113.
14.
KramperaM, GlennieS, DysonJ, ScottD, LaylorR, SimpsonE and DazziF. (2003). Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood, 101:3722–3729.
15.
BroeckxS, BorenaBM, ZimmermanM, MariënT, SeysB, SulsM, DuchateauL and SpaasJH. (2014). Intravenous application of allogenic peripheral blood-derived mesenchymal stem cells: a safety assessment in 291 equine recipients. Curr Stem Cell Res Ther, 9:452–457.
16.
CarradeDD, OwensSD, GaluppoLD, VidalMA, FerraroGL, LibrachF, BuerchlerS, FriedmanMS, WalkerNJ and BorjessonDL. (2011). Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses. Cytotherapy, 13:419–430.
17.
KolA, WoodJA, Carrade HoltDD, GilletteJA, Bohannon-WorsleyLK, PuchalskiSM, WalkerNJ, ClarkKC, WatsonJL and BorjessonDL. (2015). Multiple intravenous injections of allogeneic equine mesenchymal stem cells do not induce a systemic inflammatory response but do alter lymphocyte subsets in healthy horses. Stem Cell Res Ther, 6:73.
18.
ArdanazN, VázquezFJ, RomeroA, RemachaAR, BarrachinaL, SanzA, RaneraB, VitoriaA, AlbaredaJ, et al. (2016). Inflammatory response to the administration of mesenchymal stem cells in an equine experimental model: effect of autologous, and single and repeat doses of pooled allogeneic cells in healthy joints. BMC Vet Res, 12:65.
19.
von BahrL, BatsisI, MollG, HäggM, SzakosA, SundbergB, UzunelM, RingdenO and Le BlancK. (2012). Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells, 30:1575–1578.
20.
Le BlancK, FrassoniF, BallL, LocatelliF, RoelofsH, LewisI, LaninoE, SundbergB, BernardoME, et al. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet, 371:1579–1586.
21.
LiM, LuoX, LvX, LiuV, ZhaoG, ZhangX, CaoW, WangR and WangW. (2016). In vivo human adipose-derived mesenchymal stem cell tracking after intra-articular delivery in a rat osteoarthritis model. Stem Cell Res Ther, 7:160.
22.
FülberJ, MariaDA, da SilvaLCLC, MassocoCO, AgresteF and BaccarinR. (2016). Comparative study of equine mesenchymal stem cells from healthy and injured synovial tissues: an in vitro assessment. Stem Cell Res Ther, 7:35.
23.
de WindtTS, VonkLA, Slaper-CortenbachIC, van den BroekMP, NizakR, van RijenMHP, de WegerRA, DhertWJ and SarisDBF. (2017). Allogeneic mesenchymal stem cells stimulate cartilage regeneration and are safe for single-stage cartilage repair in humans upon mixture with recycled autologous chondrons. Stem Cells, 35:256–264.
24.
de WindtTS, VonkLA, Slaper-CortenbachIC, NizakR, van RijenMHP and SarisDBF. (2017). Allogeneic MSCs and recycled autologous chondrons mixed in a one-stage cartilage cell transplantion: a first-in-man trial in 35 patients. Stem Cells, 35:1984–1993.
25.
OliveiraRL, ChagastellesPC, SesterheimP and PrankeP. (2017). In vivo immunogenic response to allogeneic mesenchymal stem cells and the role of preactivated mesenchymal stem cells cotransplanted with allogeneic islets. Stem Cells Int, 2017:9824698.
26.
ShimG, LeeS, HanJ, KimG, JinH, MiaoW, YiT-G, ChoYK, SongSU and OhY-K. (2015). Pharmacokinetics and in vivo fate of intra-articularly transplanted human bone marrow-derived clonal mesenchymal stem cells. Stem Cells Dev, 24:1124–1132.
27.
ZhaoW, WangC, LiuR, WeiC, DuanJ, LiuK, LiS, ZouH, ZhaoJ, et al. (2016). Effect of TGF-β1 on the migration and recruitment of mesenchymal stem cells after vascular balloon injury: involvement of matrix metalloproteinase-14. Sci Rep, 6:21176.
28.
Lange-ConsiglioA, RossiD, TassanS, PeregoR, CremonesiF and ParoliniO. (2013). Conditioned medium from horse amniotic membrane-derived multipotent progenitor cells: immunomodulatory activity in vitro and first clinical application in tendon and ligament injuries in vivo. Stem Cells Dev, 22:3015–3024.
29.
ZhangH, QiuX, ShindelAW, NingH, FerrettiL, JinX, LinG, LinC-S and LueTF. (2012). Adipose tissue-derived stem cells ameliorate diabetic bladder dysfunction in a type II diabetic rat model. Stem Cells Dev, 21:1391–1400.
30.
BarryF and MurphyM. (2013). Mesenchymal stem cells in joint disease and repair. Nat Rev Rheumatol, 9:584–594.
31.
McIlwraithCW, FrisbieDD and KawcakCE. (2012). The horse as a model of naturally occurring osteoarthritis. Bone Joint Res, 1:297–309.
32.
SpaasJH, GuestDJ and Van de WalleGR. (2012). Tendon regeneration in human and equine athletes. Sports Med, 42:871–890.
33.
FerrisDJ, FrisbieDD, KisidayJD, McIlwraithCW, HagueBA, MajorMD, SchneiderRK, ZubrodCJ, KawcakCE and GoodrichLR. (2014). Clinical outcome after intra-articular administration of bone marrow derived mesenchymal stem cells in 33 horses with stifle injury. Vet Surg, 43:255–265.
34.
McIlwraithCW, FrisbieDD, RodkeyWG, KisidayJD, WerpyNM, KawcakCE and SteadmanJR. (2011). Evaluation of intra-articular mesenchymal stem cells to augment healing of microfractured chondral defects. Arthroscopy, 27:1552–1561.
35.
BroeckxS, ZimmermanM, CrocettiS, SulsM, MariënT, FergusonSJ, ChiersK, DuchateauL, Franco-ObregónA, WuertzK and SpaasJH. (2014). Regenerative therapies for equine degenerative joint disease: a preliminary study. PLoS One, 9:e85917.
36.
GirardA, FestyF and RocheR. (2013). Local anesthetics: use and effects in autologous fat grafting. Surg Curr Res, 3:1–7.
37.
ArañaM, MazoM, ArandaP, PelachoB and ProsperF. (2013). Adipose tissue-derived mesenchymal stem cells: isolation, expansion, and characterization. Methods Mol Biol 1036:47–61.
38.
O'HaraDM, XuY, LiangZ, ReddyMP, WuDY and LitwinV. (2011). Recommendations for the validation of flow cytometric testing during drug development. II assays. J Immunol Methods 363:120–134.
39.
MahaffeyEA. (2002). Chapter 10. Synovial fluid. In: Diagnostic Cytology and Hematology of the Horse. CowellRL and TylerRD, eds. Mosby, St. Louis, Missouri, pp 163–170.
40.
SteelCM. (2008). Equine synovial fluid analysis. Vet Clin North Am Equine Pract, 24:437–454.
41.
FrancozD, DesrochersA, FecteauG, DesautelsC, LatoucheJS and FortinM. (2005). Synovial fluid changes in induced infectious arthritis in calves. J Vet Intern Med, 19:336–343.
42.
RohdeC, AndersonDE, DesrochersA, St-JeanG, HullBL and RingsDM. (2000). Synovial fluid analysis in cattle: a review of 130 cases. Vet Surg, 29:341–346.
43.
MacWilliamsPS and FriedrichsKR. (2003). Laboratory evaluation and interpretation of synovial fluid. Vet Clin North Am Small Anim Pract, 33:153–178.
44.
CowellRL and TylerRD. (2002). Diagnostic Cytology and Hematology of the Horse. Mosby, St Louis, MO.
45.
European Medicine Agency. (2011). Guideline on Statistical Principles for Clinical Trials for Veterinary Medicinal Products (Pharmaceuticals). European Medicine Agency, London, United Kingdom.
46.
BourinP, BunnellBA, CasteillaL, DominiciM, KatzAJ, MarchKL, RedlH, RubinJP, YoshimuraK and GimbleJM. (2013). Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy. Cytotherapy, 15:641–648.
47.
SchnabelLV, PezzaniteLM, AntczakDF, FelippeMJB and FortierLA. (2014). Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro. Stem Cell Res Ther, 5:13.
48.
JoswigA-J, MitchellA, CummingsKJ, LevineGJ, GregoryCA, SmithR and WattsAE. (2017). Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model. Stem Cell Res Ther, 8:42.
49.
ScrevenR, KenyonE, MyersMJ, YancyHF, SkaskoM, BoxerL, BigleyEC, BorjessonDL and ZhuM. (2014). Immunophenotype and gene expression profile of mesenchymal stem cells derived from canine adipose tissue and bone marrow. Vet Immunol Immunopathol, 161:21–31.
50.
GedyeCA, HussainA, PatersonJ, SmrkeA, SainiH, SirskyjD, PereiraK, LoboN, StewartJ, et al. (2014). Cell surface profiling using high-throughput flow cytometry: a platform for biomarker discovery and analysis of cellular heterogeneity. PLoS One, 9:e105602.
51.
CabezasJ, RojasD, NavarreteF, OrtizR, RiveraG, SaraviaF, Rodriguez-AlvarezL and CastroFO. (2018). Equine mesenchymal stem cells derived from endometrial or adipose tissue share significant biological properties, but have distinctive pattern of surface markers and migration. Theriogenology, 106:93–102.
52.
RaJC, KangSK, ShinIS, ParkHG, JooSA, KimJG, KangB-C, LeeYS, NakamaK, et al. (2011). Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med, 9:181.
53.
GalipeauJ, KramperaM, BarrettJ, DazziF, DeansRJ, DeBruijnJ, DominiciM, FibbeWE, GeeAP, et al. (2016). International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy, 18:151–159.
54.
MamidiMK, NathanKG, SinghG, ThrichelvamST, YusofNA Mohd, NA FakharuziZ, ZakariaR, BhondeAK. Das and A Sen Majumdar. (2012). Comparative cellular and molecular analyses of pooled bone marrow multipotent mesenchymal stromal cells during continuous passaging and after successive cryopreservation. J Cell Biochem, 113:3153–3164.
55.
CaronJP. (2005). Intra-articular injections for joint disease in horses. Vet Clin North Am Equine Pract, 21:559–573.
56.
Rodríguez-HurtadoI, Gómez-LucasR, García-CastroJ, Mariñas-PardoL and Hermida-PrietoM. (2014). Use of allogeneic mesechymal stem cells in equine orthopaedic pathologies. Equinus, 39:48–60.
57.
SilvaAG and FurrMO. (2013). Diagnoses, clinical pathology findings, and treatment outcome of geriatric horses: 345 cases (2006–2010). J Am Vet Med Assoc, 243:1762–1768.
58.
HorohovDW, AdamsAA and ChambersTM. (2010). Immunosenescence of the Equine Immune System. J Comp Pathol, 142:S78–S84.
59.
GhoshD, McGrailDJ and DawsonMR. (2017). TGF-β1 pretreatment improves the function of mesenchymal stem cells in the wound bed. Front Cell Dev Biol, 5:28.
60.
IqbalJ, DudhiaJ, BirdJL and BaylissMT. (2000). Age-related effects of TGF-β on proteoglycan synthesis in equine articular cartilage. Biochem Biophys Res Commun, 274:467–471.
61.
JoCH, ChaiJW, JeongEC, OhS, ShinJS, ShimH and YoonKS. (2017). Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a 2-year follow-up study. Am J Sports Med 45:2774–2783.
62.
ToyserkaniNM, JørgensenMG, TabatabaeifarS, JensenCH, SheikhSP and SørensenJA. (2017). Concise review: a safety assessment of adipose-derived cell therapy in clinical trials: a systematic review of reported adverse events. Stem Cells Transl Med, 6:1786–1794.
63.
BellamyN, CampbellJ, WelchV, GeeTL, BourneR and WellsGA. (2006). Intraarticular corticosteroid for treatment of osteoarthritis of the knee. In: Cochrane Database of Systematic Reviews. BellamyN, ed. John Wiley and Sons, Ltd., Chichester, United Kingdom, p CD005328.
64.
McAlindonTE, LaValleyMP, HarveyWF, PriceLL, DribanJB, ZhangM and WardRJ. (2017). Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis. JAMA, 317:1967.
65.
MarshallJF and BlikslagerAT. (2011). The effect of nonsteroidal anti-inflammatory drugs on the equine intestine. Equine Vet J, 43:140–144.
66.
LeesP, CreedRF, GerringEE, GouldPW, HumphreysDJ, MaithoTE, MichellAR and TaylorJB. (1983). Biochemical and haematological effects of phenylbutazone in horses. Equine Vet J, 15:158–167.
67.
ReadWK. (1983). Renal `medullary crest necrosis associated with phenylbutazone therapy in horses. Vet Pathol, 20:662–669.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
